EA010428B1 - Инактивация патогена в препарате путем обработки формалином и уф светом - Google Patents
Инактивация патогена в препарате путем обработки формалином и уф светом Download PDFInfo
- Publication number
- EA010428B1 EA010428B1 EA200602206A EA200602206A EA010428B1 EA 010428 B1 EA010428 B1 EA 010428B1 EA 200602206 A EA200602206 A EA 200602206A EA 200602206 A EA200602206 A EA 200602206A EA 010428 B1 EA010428 B1 EA 010428B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formalin
- virus
- preparation
- inactivation
- light
- Prior art date
Links
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 title claims abstract description 226
- 230000002779 inactivation Effects 0.000 title claims description 86
- 244000052769 pathogen Species 0.000 title description 12
- 230000001717 pathogenic effect Effects 0.000 title description 9
- 241000700605 Viruses Species 0.000 claims abstract description 118
- 238000000034 method Methods 0.000 claims abstract description 39
- 230000000415 inactivating effect Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 31
- 229960005486 vaccine Drugs 0.000 claims description 26
- 238000000746 purification Methods 0.000 claims description 5
- 244000309457 enveloped RNA virus Species 0.000 claims description 4
- 229940127554 medical product Drugs 0.000 claims description 4
- 239000013060 biological fluid Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000010453 quartz Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 60
- 238000012360 testing method Methods 0.000 description 35
- 101710154606 Hemagglutinin Proteins 0.000 description 32
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 32
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 32
- 101710176177 Protein A56 Proteins 0.000 description 32
- 239000000185 hemagglutinin Substances 0.000 description 31
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 24
- 238000003306 harvesting Methods 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 238000004113 cell culture Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 13
- 230000005855 radiation Effects 0.000 description 13
- 238000011026 diafiltration Methods 0.000 description 12
- 230000005847 immunogenicity Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000120 cytopathologic effect Effects 0.000 description 10
- 238000011076 safety test Methods 0.000 description 10
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241001529453 unidentified herpesvirus Species 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 8
- 241000845082 Panama Species 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000012770 revaccination Methods 0.000 description 7
- 241000710942 Ross River virus Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 241000991587 Enterovirus C Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 241000712891 Arenavirus Species 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000009482 thermal adhesion granulation Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000710954 Ross river virus (STRAIN T48) Species 0.000 description 1
- 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001415849 Strigiformes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0047—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M31/00—Means for providing, directing, scattering or concentrating light
- C12M31/02—Means for providing, directing, scattering or concentrating light located outside the reactor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/11—Apparatus for generating biocidal substances, e.g. vaporisers, UV lamps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Sustainable Development (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57531004P | 2004-05-27 | 2004-05-27 | |
| PCT/EP2005/005691 WO2005118000A1 (en) | 2004-05-27 | 2005-05-26 | Inactivation of a pathogen in a sample by a treatment with formalin and uv light |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200602206A1 EA200602206A1 (ru) | 2007-04-27 |
| EA010428B1 true EA010428B1 (ru) | 2008-08-29 |
Family
ID=34968615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200602206A EA010428B1 (ru) | 2004-05-27 | 2005-05-26 | Инактивация патогена в препарате путем обработки формалином и уф светом |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1753470B1 (enExample) |
| JP (2) | JP5502276B2 (enExample) |
| KR (1) | KR101483337B1 (enExample) |
| CN (1) | CN1956739B (enExample) |
| AU (1) | AU2005249204B2 (enExample) |
| BR (1) | BRPI0511467A (enExample) |
| CA (1) | CA2567336C (enExample) |
| CR (1) | CR8805A (enExample) |
| EA (1) | EA010428B1 (enExample) |
| EC (1) | ECSP067118A (enExample) |
| ES (1) | ES2553457T3 (enExample) |
| IL (1) | IL179262A (enExample) |
| MX (1) | MXPA06013633A (enExample) |
| NO (1) | NO20065912L (enExample) |
| NZ (1) | NZ551857A (enExample) |
| WO (1) | WO2005118000A1 (enExample) |
| ZA (1) | ZA200610490B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118000A1 (en) * | 2004-05-27 | 2005-12-15 | Baxter International Inc. | Inactivation of a pathogen in a sample by a treatment with formalin and uv light |
| GB0706507D0 (en) * | 2007-04-03 | 2007-05-09 | Medi Immune Ltd | Protective device |
| ES2362990T5 (es) * | 2007-06-15 | 2017-07-20 | Amgen Inc. | Métodos de tratamiento de medios de cultivo celular para su uso en un biorreactor |
| BR112012027643A2 (pt) * | 2010-05-03 | 2016-08-16 | Glaxosmithkline Biolog Sa | métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica |
| JP5968795B2 (ja) * | 2013-01-10 | 2016-08-10 | 四国化工機株式会社 | 紫外線殺菌装置 |
| CN103992936B (zh) * | 2014-04-22 | 2015-10-07 | 北京科兴生物制品有限公司 | 一种封闭式甲醛灭活病毒管道系统及其应用 |
| US11771814B2 (en) | 2018-07-27 | 2023-10-03 | Terumo Bct Biotechnologies, Llc | Flow cell |
| CN111840596B (zh) * | 2020-06-11 | 2022-03-11 | 南岳生物制药有限公司 | 核黄素光化学血浆灭活装置及其控制系统、控制方法 |
| US20230256130A1 (en) | 2020-07-27 | 2023-08-17 | Riken | Infection prevention device and infection prevention method |
| US12447225B2 (en) | 2021-06-25 | 2025-10-21 | University Of South Florida | Ultrafast-UV laser integrating cavity mediated inactivation of a pathogen |
| CN114229953B (zh) * | 2021-12-25 | 2022-11-18 | 无锡诚源环境科技有限公司 | 腔体式紫外消毒器的紫外线剂量计算方法 |
| GB2631765A (en) * | 2023-07-13 | 2025-01-15 | Univ Cranfield | Viral inactivation reactor and method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB802048A (en) * | 1955-08-26 | 1958-09-24 | Parke Davis & Co | Vaccine products and method for producing the same |
| US3926556A (en) * | 1973-05-30 | 1975-12-16 | Raymond Marcel Gut Boucher | Biocidal electromagnetic synergistic process |
| US5247178A (en) * | 1991-12-12 | 1993-09-21 | Fusion Systems Corporation | Method and apparatus for treating fluids by focusing reflected light on a thin fluid layer |
| SU1367487A1 (ru) * | 1986-01-29 | 1995-10-27 | Институт полиомиелита и вирусных энцефалитов АМН СССР | Способ получения антирабической вакцины |
| US20020096648A1 (en) * | 2000-11-13 | 2002-07-25 | Klaus Kaiser | Apparatus for irradiating liquids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
| WO2005118000A1 (en) * | 2004-05-27 | 2005-12-15 | Baxter International Inc. | Inactivation of a pathogen in a sample by a treatment with formalin and uv light |
-
2005
- 2005-05-26 WO PCT/EP2005/005691 patent/WO2005118000A1/en not_active Ceased
- 2005-05-26 BR BRPI0511467-5A patent/BRPI0511467A/pt not_active Application Discontinuation
- 2005-05-26 CN CN2005800170355A patent/CN1956739B/zh not_active Expired - Lifetime
- 2005-05-26 ES ES05741342.9T patent/ES2553457T3/es not_active Expired - Lifetime
- 2005-05-26 MX MXPA06013633A patent/MXPA06013633A/es active IP Right Grant
- 2005-05-26 JP JP2007513806A patent/JP5502276B2/ja not_active Expired - Fee Related
- 2005-05-26 CA CA2567336A patent/CA2567336C/en not_active Expired - Lifetime
- 2005-05-26 KR KR1020117020020A patent/KR101483337B1/ko not_active Expired - Lifetime
- 2005-05-26 NZ NZ551857A patent/NZ551857A/en not_active IP Right Cessation
- 2005-05-26 EP EP05741342.9A patent/EP1753470B1/en not_active Expired - Lifetime
- 2005-05-26 AU AU2005249204A patent/AU2005249204B2/en not_active Expired
- 2005-05-26 EA EA200602206A patent/EA010428B1/ru not_active IP Right Cessation
-
2006
- 2006-11-14 IL IL179262A patent/IL179262A/en active IP Right Grant
- 2006-12-13 CR CR8805A patent/CR8805A/es unknown
- 2006-12-14 ZA ZA200610490A patent/ZA200610490B/xx unknown
- 2006-12-19 NO NO20065912A patent/NO20065912L/no not_active Application Discontinuation
- 2006-12-27 EC EC2006007118A patent/ECSP067118A/es unknown
-
2012
- 2012-04-20 JP JP2012096623A patent/JP5675690B2/ja not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB802048A (en) * | 1955-08-26 | 1958-09-24 | Parke Davis & Co | Vaccine products and method for producing the same |
| US3926556A (en) * | 1973-05-30 | 1975-12-16 | Raymond Marcel Gut Boucher | Biocidal electromagnetic synergistic process |
| SU1367487A1 (ru) * | 1986-01-29 | 1995-10-27 | Институт полиомиелита и вирусных энцефалитов АМН СССР | Способ получения антирабической вакцины |
| US5247178A (en) * | 1991-12-12 | 1993-09-21 | Fusion Systems Corporation | Method and apparatus for treating fluids by focusing reflected light on a thin fluid layer |
| US20020096648A1 (en) * | 2000-11-13 | 2002-07-25 | Klaus Kaiser | Apparatus for irradiating liquids |
Non-Patent Citations (2)
| Title |
|---|
| DARNELL M.E.R. ET AL.: "Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV" JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 121, no. 1, October 2004 (2004-10), pages 85-91, XP004551409 ISSN: 0166-0934 paragraphs '02.3!, '02.6!, '03.1!, '03.3! * |
| DATABASE WPI Section Ch, Week 199627 Derwent Publications Ltd., London, GB; Class A96, AN 1996-266694 XP002337093 & SU 1367487 A1 (A MED POLYMIELITIS VIRAL ENCEPHELITIS) 27 October 1995 (1995-10-27) abstract * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL179262A (en) | 2011-01-31 |
| EP1753470A1 (en) | 2007-02-21 |
| NO20065912L (no) | 2007-02-26 |
| KR20110099810A (ko) | 2011-09-08 |
| AU2005249204A1 (en) | 2005-12-15 |
| ECSP067118A (enExample) | 2007-02-28 |
| JP2012143249A (ja) | 2012-08-02 |
| CR8805A (es) | 2007-06-19 |
| BRPI0511467A (pt) | 2007-12-26 |
| JP2008500303A (ja) | 2008-01-10 |
| EA200602206A1 (ru) | 2007-04-27 |
| IL179262A0 (en) | 2007-03-08 |
| CN1956739A (zh) | 2007-05-02 |
| EP1753470B1 (en) | 2015-08-19 |
| JP5502276B2 (ja) | 2014-05-28 |
| CA2567336C (en) | 2010-11-23 |
| WO2005118000A1 (en) | 2005-12-15 |
| MXPA06013633A (es) | 2007-03-23 |
| KR101483337B1 (ko) | 2015-01-15 |
| CN1956739B (zh) | 2011-12-28 |
| CA2567336A1 (en) | 2005-12-15 |
| NZ551857A (en) | 2009-11-27 |
| HK1105374A1 (en) | 2008-02-15 |
| ZA200610490B (en) | 2008-10-29 |
| JP5675690B2 (ja) | 2015-02-25 |
| AU2005249204B2 (en) | 2010-07-15 |
| ES2553457T3 (es) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5675690B2 (ja) | ホルマリンおよびｕｖ光での処理によるサンプル中の病原体の不活化 | |
| Darnell et al. | Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV | |
| ES2270501T3 (es) | Procedimiento para la inactivacion de virus envueltos. | |
| AU764592B2 (en) | Methods and compositions for the selective modification of nucleic acids | |
| KR101760844B1 (ko) | 바이러스성 백신의 제조 방법 | |
| US8703467B2 (en) | Inactivation of a pathogen in a sample by a treatment with formalin and UV light | |
| RU2466742C2 (ru) | Способ инактивирования патогенов в донорской крови, плазме крови или концентратах эритроцитов в гибких контейнерах с помощью встряхивания | |
| Gracheva et al. | Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light | |
| US6165711A (en) | Process for disintegrating nucleic acids and preparing biological products of guaranteed quality | |
| Vaidya et al. | Ultraviolet-C irradiation for inactivation of viruses in foetal bovine serum | |
| JPS61158783A (ja) | ヒトの腫瘍白血病ウイルス３のソラレンによる不活化 | |
| Wiktor et al. | Immunogenicity of rabies virus inactivated by β-propiolactone, acetylethyleneimine, and ionizing irradiation | |
| JP2021519782A (ja) | 照射によって不活化されたポリオウイルス、それを含む組成物、および調製方法 | |
| KR20070030852A (ko) | 포르말린 및 ｕｖ광으로의 처리에 의한 샘플 중 병원균의불활성화 | |
| CA2716426A1 (en) | Inactivation of a pathogen in a sample by a treatment with formalin and uv light | |
| HK1105374B (en) | A method for inactivating a virus contained in a sample | |
| US20250177534A1 (en) | Thermostable uv inactivated vaccines and other biopharmaceuticals | |
| Eftekhari et al. | Evaluation of the effects of concentration, duration and temperature of incubation with Beta-Propiolactone on inactivation of cell-derived rabies virus | |
| JP2009005589A (ja) | Ｕｖによるｃ型肝炎ウイルスの不活化方法 | |
| Zarubaev et al. | Photodynamic inactivation of enveloped viruses by fullerene: study of efficacy and safety | |
| SU903380A1 (ru) | Ингибитор вирусов | |
| Mirshafiee et al. | Induction of nucleic acid damage in viral genomes using riboflavin in combination with UV Light | |
| Mayerhofer et al. | UV irradiation for the manufacturing of viral vaccines: state-of-the-art and perspectives in modern vaccine processing | |
| Mirshafiee et al. | Induction of Nucleic Acid Damage in Viral Genomes using Riboflavin in Combination with UV Light |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |